In a report released yesterday, Sandy Draper from SunTrust Robinson reiterated a Buy rating on Teladoc (NYSE: TDOC), with a price target of $77. The company’s shares closed yesterday at $69.35, close to its 52-week high of $71.30.
According to TipRanks.com, Draper is a 5-star analyst with an average return of 20.5% and a 78.9% success rate. Draper covers the Services sector, focusing on stocks such as PRA Health Sciences, Charles River Labs, and IQVIA Holdings Inc.
Teladoc has an analyst consensus of Strong Buy, with a price target consensus of $68.47, implying a -1.3% downside from current levels. In a report issued on July 24, Canaccord Genuity also maintained a Buy rating on the stock with a $70 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.30 and a one-year low of $27.30. Currently, Teladoc has an average volume of 1.33M.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TDOC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.
